Palvella targets 2H 2026 NDA filing while outlining >$1B peak U.S. sales potential for QTORIN rapamycin in microcystic lymphatic malformations
Palvella Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $112.59
-10.0% in 7d after detection
Post-detection moves
1h
—
1d
+0.7%
3d
-0.6%
7d
-10.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS